Olema Pharmaceuticals, Inc. (OLMA)

NASDAQ:
OLMA
| Latest update: Mar 9, 2026, 6:52 PM

Price Chart

$17.23

20.05%
(1 month)

Top Shareholders

Bain Capital Holdings LP
10.82%
Paradigm BioCapital Advisors LP
9.59%
Janus Henderson Group Plc
8.53%
BlackRock, Inc.
7.07%
BVF, Inc.
6.73%
FMR LLC
6.39%
Deep Track Capital LP
5.08%
The Vanguard Group, Inc.
4.53%

Sentiment for OLMA

News
Social

Buzz Talk for OLMA

Today

Social Media

General

Stock events for Olema Pharmaceuticals, Inc. (OLMA)

Olema Pharmaceuticals' stock experienced a 30% drop in October 2025 following the ESMO data presentation on palazestrant. In November 2025, Olema closed a $218.5 million public offering of common stock and announced a strategic collaboration in immuno-dermatology, leading to a pre-market surge. Insiders have sold more company stock than they have bought in the past six months. In February-March 2026, the company attracted Wall Street attention with analyst upgrades and new coverage. The departure of the COO/CFO in January 2026 impacted investor sentiment. The stock has gained over 110% in the past six months and 470.55% over the past year.

Demand Seasonality affecting Olema Pharmaceuticals, Inc.’s stock price

Product demand seasonality is not a significant factor for Olema Pharmaceuticals, as its products are still in clinical development. However, December has historically been a weaker month for OLMA's share price, while February and July have often seen an uplift, attributed to investor behavior rather than product demand.

Overview of Olema Pharmaceuticals, Inc.’s business

Olema Pharmaceuticals, Inc. (OLMA) is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing targeted therapies for women's cancers. Their lead product candidate, palazestrant (OP-1250), is in Phase 3 clinical trials for ER+/HER2- breast cancer, both as a monotherapy and in combination with other inhibitors. Additionally, Olema is developing OP-3136, a KAT6 inhibitor in Phase 1 clinical trials for ER+/HER2- metastatic breast cancer and other cancers.

OLMA’s Geographic footprint

Olema Pharmaceuticals, Inc. is headquartered in San Francisco, California, and maintains operations in Cambridge, Massachusetts.

OLMA Corporate Image Assessment

Olema Pharmaceuticals generally has a positive brand reputation, with a consensus rating of "Moderate Buy" from analysts. Palazestrant is viewed optimistically for its potential in the ER+/HER2- breast cancer market. However, the stock drop after ESMO 2025 and the departure of the COO/CFO have affected its reputation and stock performance.

Ownership

Olema Pharmaceuticals, Inc. has high institutional ownership, ranging from approximately 91.78% to 132.15%. Major institutional owners include Bain Capital Life Sciences Investors LLC, Paradigm Biocapital Advisors LP, and Janus Henderson Group Plc. Insider ownership stands at approximately 16.36%.

FAQ

What is the current stock price of Olema Pharmaceuticals, Inc.?

As of the latest update, Olema Pharmaceuticals, Inc.'s stock is trading at $17.23 per share.

What’s happening with Olema Pharmaceuticals, Inc. stock today?

Today, Olema Pharmaceuticals, Inc. stock is down by -20.05%, possibly due to news.

What is the market sentiment around Olema Pharmaceuticals, Inc. stock?

Current sentiment around Olema Pharmaceuticals, Inc. stock is negative, based on recent news, trading volume, and analyst opinions.

Is Olema Pharmaceuticals, Inc.'s stock price growing?

Over the past month, Olema Pharmaceuticals, Inc.'s stock price has decreased by -20.05%.

How can I buy Olema Pharmaceuticals, Inc. stock?

You can buy Olema Pharmaceuticals, Inc. stock through any brokerage platform, such as e.g., Robinhood, Fidelity, E*TRADE, by searching for the ticker symbol OLMA

Who are the major shareholders of Olema Pharmaceuticals, Inc. stock?

Major shareholders of Olema Pharmaceuticals, Inc. include institutions such as Bain Capital Holdings LP (10.82%), Paradigm BioCapital Advisors LP (9.59%), Janus Henderson Group Plc (8.53%) ... , according to the latest filings.